Silva Francisco's Form 4 filing
BioRestorative Therapies, Inc. (BRTX) · filed Sep 9, 2022
- Accession no.
- 0001567619-22-017246
- Filed
- Sep 9, 2022
- Trade date
- Aug 26-29, 2022
- Filing delay
- 14 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions. Open-market purchases total $18.8K. Open-market sales total $13.4K. It was filed 14 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Silva FranciscoCIK 0001527241 | Director, Officer (VP of Research and Development) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 26, 2022 | Common Stock | SSaleDisposed | −3,958 | $3.39F1 | −$13,417.62 | 158,156 | Direct | |
| Aug 26, 2022 | Common Stock | PPurchaseAcquired | +2,600 | $3.35 | +$8,710 | 160,756 | Direct | |
| Aug 29, 2022 | Common Stock | PPurchaseAcquired | +2,816 | $3.21F3 | +$9,039.36 | 163,572 | Direct | |
| Aug 29, 2022 | Common Stock | PPurchaseAcquired | +307 | $3.32F4 | +$1,019.24 | 12,136 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents transaction inadvertently effected by the reporting person. This transaction was executed in multiple trades at prices ranging from $3.33 to $3.45 per share. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $3.21 to $3.2159 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $3.28 to $3.35 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.